Zhengye Biotechnology Holding Limited
NASDAQ:ZYBTDrug Manufacturers - Specialty & Generic
+$7.31 today
- Market cap
- $71.09M
- Beta
- -2.17
- P/E (TTM)
- -36.3
- EPS (TTM)
- -$1.50
Volume 0.02M
Average 0.10M
ZYBT Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Zhengye Biotechnology Holding LimitedNASDAQ: ZYBT
Depreciation & Amortization · Q4 FY2025 · quarter ended Dec 2025
Depreciation & amortization of CN¥13.45M in Q4 FY2025
Q4 FY2025 depreciation & amortization was CN¥13.45M. Over 3 fiscal years it compounded at +11.3% a year.
Context
- Depreciation & amortization amounted to 22.3% of revenue in FY2025, up 9.3 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
CNY · from the cash flow
- Latest · FY2025
- 25.96M CNY
- Year-over-year change
- +7.4%
- 4-year CAGR
- +12.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.96M | +7.4% |
| FY2024 | 2024-12-31 | 24.16M | +1.0% |
| FY2023 | 2023-12-31 | 23.91M | +27.2% |
| FY2022 | 2022-12-31 | 18.8M | +17.4% |
| FY2021 | 2021-12-31 | 16.01M | — |
Depreciation & Amortization vs competitors
How ZYBT compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +7.4% is the 3rd highest of 9, against a peer median of -73.1%.
- Depreciation & amortization amounts to 22.3% of revenue for ZYBT, versus a peer median of 2.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | CN¥25.96M CNY | +7.4% | +11.3% | 22.3% | |
| LTM Mar 2026 | $1.3M USD | +5.8% | +19.5% | 1.7% | |
| LTM Mar 2026 | $917K USD | +9.7% | +7.5% | 1608.8% | |
| LTM Mar 2026 | $719K USD | +24.0% | -9.7% | 1.3% | |
| LTM Mar 2026 | $308K USD | -77.1% | -35.0% | 4.1% | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $219.19K USD | -179.7% | — | — |
| LTM Mar 2026 | CA$103.77K CAD | -69.2% | -22.6% | — | |
| LTM Mar 2026 | CA$75.25K CAD | -81.1% | -37.4% | — | |
| LTM Mar 2026 | $48K USD | -98.5% | -55.3% | — | |
| Peer median (excluding ZYBT) | — | -73.1% | -22.6% | 2.9% | |
Competitors are the stored peer set for ZYBT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 46.47M | 55.74M | 37.51M | 13.47M | (82.97M) |
| Depreciation & Amortization | 16.01M | 18.8M | 23.91M | 24.16M | 25.96M |
| Deferred Income Tax | (358K) | (1.09M) | 758K | 924K | 11.1M |
| Stock-Based Compensation | 0 | 0 | 0 | 0 | 0 |
| Change in Working Capital | (33.71M) | (66.82M) | (20.49M) | (977K) | 44.83M |
| Accounts Receivables | (40.91M) | (47.38M) | 38.05M | 11.31M | 61.41M |
| Inventory | (12.34M) | (12.33M) | (12.9M) | (5.88M) | 6.25M |
| Accounts Payables | 17.63M | (9.67M) | (35.61M) | (404K) | (3.36M) |
| Other Working Capital | 1.91M | 2.56M | (10.03M) | (6M) | (19.47M) |
| Other Non-Cash Items | 3.4M | 10.7M | 6.5M | 3.47M | 14.42M |
| Operating Cash Flow | 31.81M | 17.34M | 48.18M | 41.05M | 13.33M |
| Capital Expenditures | (26.4M) | (27.33M) | (11.6M) | (27.77M) | (12.63M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (1.22M) | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (7.21M) | 0 | (3.15M) | (14.08M) | (11.62M) |
| Investing Cash Flow | (26.27M) | (27.33M) | (11.77M) | (27.67M) | (12.63M) |
| Debt Repayment | 8M | 34.88M | 24.97M | (2.74M) | (12.09M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 43.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (11.05M) | (21.43M) | (39.45M) | (16.02M) | 0 |
| Other Financing Activities | 0 | (1) | (4.5M) | (3.37M) | 1.32M |
| Financing Cash Flow | (3.05M) | 13.46M | (18.98M) | (22.13M) | 32.31M |
| Effect of Forex Changes | 0 | 0 | 0 | 168K | (1.29M) |
| Net Change in Cash | 2.49M | 3.46M | 17.44M | (8.58M) | 31.73M |
| Free Cash Flow | 5.41M | (9.99M) | 36.58M | 13.27M | 703K |
Zhengye Biotechnology Holding Limited
NASDAQ:ZYBT
Intrinsic Alpha fair value
Locked
Current Price
$1.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.